Affimed N.V.
NASDAQ:AFMD 12:01:14 AM EDT
| Market Cap (Intraday) | 76.90M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $5.19 |
| 50-Day MA | $5.58 |
| 200-Day MA | $5.14 |
Affimed N.V. Stock, NASDAQ:AFMD
Gottlieb-Daimler-Strasse 2, Im Neuenheimer Feld 582, Mannheim, Baden Wuerttemberg 68165
Germany
Phone: +49.621.560.030
Number of Employees: 78
Description
Affimed NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of cancer immunotherapies. The company�s proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. It operates through the Germany and USA geographical segments. The company was founded in 2000 and is headquartered in Mannheim, Germany.